NYSE:JNJ
Johnson & Johnson (JNJ-N)
Financials
Technical Analysis
Buy, Sell or Hold?
Related posts
Nervous markets await Nvidia
Apr 16, 2025, 12:00 amThis summary was created by AI, based on 26 opinions in the last 12 months.
Johnson & Johnson (JNJ) is viewed largely favorably among analysts despite ongoing challenges, notably the talcum powder litigation, which many believe could soon be resolved, leading to a potential rebound in stock performance. The company has a strong presence in the pharmaceutical and medical devices sectors following a recent spinoff, and it boasts a pristine balance sheet with a history of dividend increases. Analysts highlight the attractive valuation, with a price-to-earnings ratio in the low 14s, bolstered by a solid dividend yield around 3.3%. Social media buzz surrounding the company has surged, reflecting increased interest, and many experts suggest that now may be a good time to buy given its relatively low price and stable financials. The consensus is that, while the stock has faced some pressures, it presents a compelling opportunity for long-term investors willing to ride out current volatility.
Premium contentAt Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That’s why for almost 140 years, we have aimed to keep people well at every age and every stage of life. Today we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. Social media mentions are up 18% in the past 24h.
It reports Tuesday when we should get a legal update about those suing JNJ for cancer allegedly being in their talcum powder. It's been stuck in a range forever, though not in a perpetual downturn like other pharma. This could turn around on any big news on any new drug.
Premium contentAfter spinoff, now just pharma and medical technologies/devices. One of 2 AAA-rated US companies (the other is MSFT). Pristine balance sheet forever. Divvy increases for 62 consecutive years, all from free cashflow. Crazy-cheap valuation of 14-15x PE, partly due to ongoing talc litigation. Yield is 3.34%.
Recent press release was like none other. Company stated talc litigation based on fake science; if the other side won't settle, JNJ will litigate each and every case separately. He suspects this is a ploy to force a settlement. Expects it to be over by year's end.
Premium contentIs a hodge-podge of consumer products, some medical business and an also-ran in businesses like hips and knees. This has always traded at a premium for being a well-run consumer package company that money managers can't get fired for owning. It's so big that it needs to be broken up.
Premium contentJohnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas, such as immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular & metabolic diseases. Social media mentions are up 250% in the past 24h.
Premium contentThe consumer product monster has increased debt lately, but analysts feel comfortable with the low debt to earnings ratio. This is allowing the company to continue growing cash reserves. It trades at 24x earnings and supports a 20% ROE. We recommend setting a stop-loss at $133 looking to achieve $174 -- upside potential of 19%. Yield 3.3%
(Analysts’ price target is $174.28)
Johnson & Johnson(JNJ-N) Rating
Ranking : 4 out of 5
Bullish - Buy Signals / Votes : 3
Neutral - Hold Signals / Votes : 3
Bearish - Sell Signals / Votes : 3
Total Signals / Votes : 9
Johnson & Johnson(JNJ-N) Frequently Asked Questions
What is Johnson & Johnson stock symbol?
Johnson & Johnson is a American stock, trading under the symbol JNJ-N on the New York Stock Exchange (JNJ). It is usually referred to as NYSE:JNJ or JNJ-N
Is Johnson & Johnson a buy or a sell?
In the last year, 9 stock analysts published opinions about JNJ-N. 3 analysts recommended to BUY the stock. 3 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Johnson & Johnson.
Is Johnson & Johnson a good investment or a top pick?
Johnson & Johnson was recommended as a Top Pick by on . Read the latest stock experts ratings for Johnson & Johnson.
Why is Johnson & Johnson stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
Is Johnson & Johnson worth watching?
9 stock analysts on Stockchase covered Johnson & Johnson In the last year. It is a trending stock that is worth watching.
What is Johnson & Johnson stock price?
On 2025-06-27, Johnson & Johnson (JNJ-N) stock closed at a price of $152.41.
High in 2022, series of lower highs and lower lows since then. Only positive is that on the most recent pullback it pulled back to a higher low. If you own it as one position among many, you probably won't lose a bunch of $$. Doesn't see it being a leading stock in the near term.
Lean into companies that are economically sensitive with pricing power; if their costs go up tomorrow, they can raise prices the next day.